Clinical trials: Gametocytes
Malaria
Clinical Investigation Study to Evaluate the Consistency and Reproducibility of Two Consecutive Mosquito Feeding Assays
The proposed trial design has been developed to assess the consistency and reproducibility of two consecutive direct skin feeding assays (DSFA) at 24-hour interval.
- Trial name
- NCT04666350
- Testing
- Direct Skin Feeding Assay (DSFA), Primaquine, Artemether/Lumefantrine
- Where
- Kenya
- Volunteers
- 42 people
- Sponsor
- PATH
Malaria
P. Falciparum Infection Dynamics and Transmission to Inform Elimination (INDIE-1a)
In the current randomized trial, the investigators will test the ability of two experimental approaches to malaria infection management to reduce malaria transmission potential.
- Trial name
- NCT03705624
- Testing
- Enhanced Community Case Management (CCM), Monthly Screening and Treatment (MSAT)
- Where
- Burkina Faso
- Volunteers
- 907 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Uncomplicated Falciparum Malaria
Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials
Single-center phase II/III clinical investigation of the pharmacokinetics and pharmacodynamics of artemether-lumefantrine and dihydroartemisinin-piperaquine for gametocyte clearance and post-treatment chemoprotection in Zambian…
- Trial name
- NCT04009343
- Testing
- Artemether-lumefantrine, Dihydroartemisinin-piperaquine
- Where
- Zambia
- Volunteers
- 182 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Malaria
Malaria Transmission in Humans and Mosquitoes at the Area of Sabou, Burkina Faso
Background: Malaria is a disease that affects many people in Burkina Faso. It is caused by germs that are spread by mosquito bites. A vaccine that blocks the spread of malaria is important to get rid of the disease.
- Trial name
- NCT04650815
- Where
- 2 sites in Burkina Faso
- Volunteers
- 608 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Background: Malaria is a disease that affects many people in Liberia. It is caused by germs (parasites) that are spread by mosquito bites.
- Trial name
- NCT04704674
- Where
- Liberia
- Volunteers
- 396 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Artesunate Plus Sulfadoxine-pyrimethamine Pharmacokinetics, Efficacy, Gametocytes Carriage and Birth Outcomes in Pregnant Women With Malaria
The main purpose of this study is to compare the drug levels of artesunate and sulfadoxine-pyrimethamine found in pregnant women with malaria to those drug levels found in non-pregnant women from other studies.
- Trial name
- NCT00331708
- Testing
- Artesunate plus sulfadoxine-pyrimethamine
- Where
- Mozambique
- Volunteers
- 3 people
- Sponsor
- Professor Karen I Barnes
Malaria, Asymptomatic Malaria
Low Dose Primaquine for Clearance of Gametocytes
Primaquine (PQ) is currently the only available drug that can clear mature transmission stages of P. falciparum parasites. PQ was previously shown to clear gametocytes that persist after artemisinin-combination therapy.
- Conditions
- Malaria, Asymptomatic Malaria, Plasmodium Falciparum
- Trial name
- LOPRIM (NCT01935882)
- Testing
- Artemether-lumefantrine combination, Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine, Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
- Where
- Burkina Faso
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Community Dynamics of Malaria Transmission in Humans and Mosquitoes at Maferinyah Sub-Prefecture, Guinea
Background: Half of the world s population is at risk of malaria. In 2015, there were 214 million cases of malaria and 438,000 deaths. A transmission-blocking vaccine (TBV) could help end the disease.
- Trial name
- NCT04969913
- Where
- 2 sites in United States, Guinea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum
Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission
The purpose of this study is to assess the gametocytocidal and transmission reducing activity of pyronaridine-artesunate (PA) and dihydroartemisinin-piperaquine (DP) with and without a single low dose of primaquine (PQ…
- Trial name
- NECTAR1 (NCT04049916)
- Testing
- Pyronaridine Tetraphosphate/Artesunate, Dihydroartemisinin/Piperaquine, Primaquine Diphosphate
- Where
- 2 sites in Mali, Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria
The purpose of this study is to compare the efficacy of sulfadoxine-pyrimethamine plus artesunate with that of sulfadoxine-pyrimethamine on its own for the treatment of uncomplicated malaria.
- Trial name
- NCT00203736
- Testing
- Sulfadoxine-pyrimethamine, Artesunate plus sulfadoxine-pyrimethamine
- Where
- 2 sites in Mozambique
- Volunteers
- 240 people
- Sponsor
- University of Cape Town